General Information of Binding Target of SBP (BTS) (ID: ST00092)
BTS Name
Myeloid cell surface antigen CD33
Synonyms
Sialic acid-binding Ig-like lectin 3; Siglec-3; gp67; CD antigen CD33
BTS Type
Protein
Family
Immunoglobulin superfamily;
SIGLEC (sialic acid binding Ig-like lectin) family
Gene Name
CD33
Organism
Homo sapiens (Human)
Function
Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2 In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K
UniProt ID
P20138
UniProt Entry
CD33_HUMAN
PFam
PF00047 ; PF07686
Gene ID
945
Sequence
MPLLLLLPLLWAGALAMDPNFWLQVQESVTVQEGLCVLVPCTFFHPIPYYDKNSPVHGYW
FREGAIISRDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRM
ERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPGHSKNLTCSVSWACEQGTPPIFSWL
SAAPTSLGPRTTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLNVTYVPQNPTT
GIFPGDGSGKQETRAGVVHGAIGGAGVTALLALCLCLIFFIVKTHRRKAARTAVGRNDTH
PTTGSASPKHQKKSKLHGPTETSSCSGAAPTVEMDEELHYASLNFHGMNPSKDTSTEYSE
VRTQ
Sequence Length
364
Synthetic Binding Protein (SBP) Targeting This BTS
SBP Name Highest Status Mechanism Affinity Application Details Ref
BiTE AMG-673 Phase I; Suspended Inhibitor N.A. Acute myeloid leukaemia [ICD-11: XH8AA5]
SBP Info
[1]
BiTE Eluvixtamab Phase I Inhibitor N.A. Acute myeloid leukaemia [ICD-11: XH8AA5]
SBP Info
[2], [1]
scFv Emerfetamab Phase I Binder N.A. Acute myeloid leukaemia [ICD-11: XH8AA5]
SBP Info
[3]
References
1 Amgen. Product Development Pipeline. 2021.
2 Harnessing T cells to fight cancer with BiTE? antibody constructs--past developments and future directions. Immunol Rev. 2016 Mar;270(1):193-208.
3 Therapeutic Structural Antibody Database. Emerfetamab